Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's diseaseEmraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophreniaCerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decadeAbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $2.92-$2.96NORTH CHICAGO, Ill., Aug.

Cerevel的临床阶段资产补充了AbbVie新兴的神经科学渠道，并在精神病学，偏头痛和帕金森氏病领域领先市场品牌。雷克立定是一种潜在的同类最佳的下一代抗精神病药物，正在进行试验，旨在为精神分裂症患者注册。对于AbbVie来说，雷克立定是一种强有力的战略选择，有可能对未来十年的收入产生重大影响。AbbVie重申了之前发布的2024年全年调整稀释每股收益指导范围为10.71美元至10.91美元；重申之前发布的第三季度调整后稀释每股收益指导范围为2.92美元至2.96美元，伊利诺伊州北芝加哥，8月。

1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE). With the completion of the acquisition, Cerevel is now part of AbbVie..

12024/PRNewswire/-AbbVie（纽约证券交易所：ABBV）今天宣布，它已完成对Cerevel Therapeutics（纳斯达克：CERE）的收购。收购完成后，Cerevel现在是AbbVie的一部分。。

'AbbVie's acquisition of Cerevel strengthens our foundation in neuroscience and positions us to deliver sustainable long-term performance into the next decade and beyond,' said Robert A. Michael, chief executive officer, AbbVie. 'Our new Cerevel colleagues share our commitment to deliver meaningful change for patients living with neurological and psychiatric conditions.

AbbVie首席执行官罗伯特·迈克尔（RobertA.Michael）说，AbbVie收购Cerevel加强了我们在神经科学方面的基础，使我们能够在未来十年及以后取得可持续的长期业绩我们新的Cerevel同事与我们一样致力于为患有神经和精神疾病的患者提供有意义的改变。

We are excited to welcome the talented Cerevel team to AbbVie.'.

我们很高兴欢迎才华横溢的Cerevel团队来到AbbVie。”。

There are multiple programs in Cerevel's pipeline across several neurological and psychiatric conditions such as schizophrenia, Parkinson's disease and mood disorders, where there continues to be significant unmet need for patients. Cerevel's pipeline is highly complementary to AbbVie's existing neuroscience portfolio and the completion of the acquisition is an important step forward to delivering new and better tolerated therapies..

Cerevel的管道中有多个项目涉及多种神经和精神疾病，如精神分裂症、帕金森病和情绪障碍，这些疾病对患者的需求仍然没有得到满足。Cerevel的管道与AbbVie现有的神经科学投资组合高度互补，收购的完成是向提供新的和耐受性更好的疗法迈出的重要一步。。

Emraclidine, a potential best-in-class, next-generation antipsychotic, is a positive allosteric modulator (PAM) of the muscarinic M4 receptor that is being studied for the treatment of schizophrenia – a disease that affects approximately 24 million people worldwide.1 In a Phase 1b study, emraclidine has shown promising efficacy and safety and is currently completing two Phase 2 trials that were designed to be registration enabling..

Emraclidine是一种潜在的同类最佳的下一代抗精神病药物，是毒蕈碱M4受体的正变构调节剂（PAM），正在研究用于治疗精神分裂症-一种影响全球约2400万人的疾病。1在1b期研究中，Emraclidine显示出有希望的疗效和安全性，目前正在完成两项旨在进行登记的2期试验。。

Tavapadon, a first-in-class dopamine D1/D5 selective partial agonist for the management of Parkinson's disease, is currently in Phase 3 studies and has potential for both monotherapy and adjunctive treatment. Tavapadon's efficacy and safety-tolerability profile could enable its utility in early Parkinson's disease, becoming a near-term complementary asset to AbbVie's existing symptomatic therapies for advanced Parkinson's disease.

Tavapadon是用于治疗帕金森氏病的一流多巴胺D1/D5选择性部分激动剂，目前正在进行3期研究，具有单药治疗和辅助治疗的潜力。Tavapadon的疗效和安全耐受性可以使其在早期帕金森病中发挥作用，成为AbbVie现有的晚期帕金森病对症治疗的短期补充资产。

Recently, tavapadon met the primary endpoint in a pivotal Phase 3 study and data from additional Phase 3 trials of tavapadon are expected later this year..

最近，塔瓦帕顿在一项关键的3期研究中达到了主要终点，预计今年晚些时候将有来自塔瓦帕顿其他3期试验的数据。。

CVL-354, currently in Phase 1, is a potential best-in-class kappa opioid receptor (KOR) antagonist that has the potential to provide significantly improved efficacy and tolerability compared to existing treatments for major depressive disorder (MDD). Darigabat, currently in Phase 2, is an alpha 2/3/5 selective GABAA receptor PAM for treatment-resistant epilepsy and panic disorder..

目前处于第1阶段的CVL-354是一种潜在的同类最佳κ阿片受体（KOR）拮抗剂，与现有的重度抑郁症（MDD）治疗方法相比，它有可能提供显着改善的疗效和耐受性。Darigabat目前处于第二阶段，是一种α2/3/5选择性GABAA受体PAM，用于治疗耐药性癫痫和惊恐障碍。。

For additional background on the acquisition, please read the announcement press release here and view AbbVie's investor presentation here.

有关此次收购的其他背景信息，请阅读此处的公告新闻稿，并在此处查看AbbVie的投资者介绍。

Financial Terms

财务条款

AbbVie has acquired all outstanding Cerevel common stock for $45.00 per share. It is expected that Cerevel's common stock will cease to trade on the NASDAQ stock exchange prior to market open on August 1, 2024. This acquisition is expected to be accretive to adjusted diluted earnings per share (EPS) beginning in 2030..

AbbVie以每股45.00美元的价格收购了所有已发行的Cerevel普通股。预计Cerevel的普通股将在2024年8月1日开市前停止在纳斯达克证券交易所交易。预计此次收购将从2030年开始增加调整后的稀释每股收益（EPS）。。

Full-Year 2024 Outlook

2024年全年展望

AbbVie is reaffirming its previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91. This guidance includes a $0.19 per share dilutive impact related to the completed Cerevel acquisition. AbbVie's 2024 adjusted diluted EPS guidance includes an unfavorable impact of $0.60 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter.

AbbVie重申其之前发布的2024年全年调整稀释每股收益指导范围为10.71美元至10.91美元。该指导包括与完成的Cerevel收购相关的每股0.19美元的稀释影响。AbbVie 2024年调整后的稀释每股收益指导意见包括每股0.60美元的不利影响，该不利影响与收购的知识产权和开发以及截至今年第二季度的里程碑费用有关。

The company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the second quarter of 2024, as both cannot be reliably forecasted..

该公司2024年调整后的稀释每股收益指导不包括2024年第二季度以后可能产生的收购知识产权和开发以及里程碑的任何影响，因为两者都无法可靠预测。。

AbbVie is reaffirming its previously issued 2024 third-quarter adjusted diluted EPS guidance range of $2.92-$2.96. AbbVie's 2024 third-quarter adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred in the quarter, as both cannot be reliably forecasted..

AbbVie重申其之前发布的2024年第三季度调整后稀释每股收益指导范围为2.92-2.96美元。艾伯维2024年第三季度调整后的稀释每股收益指导不包括本季度可能产生的收购知识产权和开发以及里程碑的任何影响，因为两者都无法可靠预测。。

__________________

__________________

1 World Health Organization: Schizophrenia Key Facts. Available at: https://www.who.int/news-room/fact- sheets/detail/schizophrenia. January 10, 2022.

1世界卫生组织：精神分裂症关键事实。网址：https://www.who.int/news-room/fact-床单/细节/精神分裂症。2022年1月10日。

About AbbVie in Neuroscience

关于神经科学中的AbbVie

At AbbVie, our commitment to preserving personhood of people around the world living with neurological and psychiatric disorders is unwavering. With more than three decades of experience in neuroscience, we are providing meaningful treatment options today and advancing innovation for the future. AbbVie's Neuroscience portfolio consists of approved treatments in neurological conditions, including migraine, movement disorders and psychiatric disorders, along with a robust pipeline of transformative therapies.

在艾伯维，我们坚定不移地致力于保护世界各地患有神经和精神疾病的人的人格。凭借30多年的神经科学经验，我们今天正在提供有意义的治疗选择，并推动未来的创新。AbbVie的神经科学投资组合包括批准的神经疾病治疗，包括偏头痛，运动障碍和精神疾病，以及强大的转化疗法。

We have made a strong investment in research and are committed to building a deeper understanding of neurological and psychiatric disorders. Every challenge makes us more determined and drives us to discover and deliver advancements for those impacted by these conditions, their care partners and clinicians.

我们在研究方面进行了大量投资，并致力于加深对神经和精神疾病的了解。每一个挑战都使我们更有决心，并促使我们发现并为那些受这些疾病影响的人、他们的护理合作伙伴和临床医生提供进步。

For more information, visit www.abbvie.com..

有关更多信息，请访问www.abbvie.com。。

About AbbVie

关于AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio.

AbbVie的使命是发现并提供创新药物和解决方案，以解决当今严重的健康问题，并应对未来的医疗挑战。我们致力于在免疫学、肿瘤学、神经科学和眼部护理等几个关键治疗领域，以及Allergan美学产品组合中的产品和服务，对人们的生活产生重大影响。

For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube..

有关AbbVie的更多信息，请访问www.AbbVie.com。在LinkedIn、Facebook、Instagram、X（以前的Twitter）和YouTube上关注@AbbVie。。

Forward-Looking Statements

前瞻性声明

Some statements in this news release, including those relating to the acquisition of Cerevel by AbbVie, are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions and uses of future or conditional verbs, generally identify forward- looking statements.

本新闻稿中的一些声明，包括与AbbVie收购Cerevel有关的声明，是或可能被视为1995年《私人证券诉讼改革法案》中的前瞻性声明。单词“相信”、“期望”、“预期”、“项目”以及类似的将来动词或条件动词的表达和用法通常表示前瞻性陈述。

AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period, the risk that the businesses will not be integrated successfully, disruption from the transaction making it more difficult to maintain business and operational relationships, negative effects of the consummation of the acquisition on the market price of AbbVie's common stock and/or operating results, significant transaction costs, unknown liabilities, the risk of litigation and/or regulatory actions related to the acquisition or Cerevel's business, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry.

AbbVie警告称，这些前瞻性声明存在风险和不确定性，可能导致实际结果与前瞻性声明中明示或暗示的结果存在重大差异。此类风险和不确定性包括但不限于与实现收购预期收益的能力相关的风险，包括收购预期收益无法实现或无法在预期时间内实现的可能性，业务无法成功整合的风险，交易中断使维持业务和运营关系更加困难，收购完成对AbbVie普通股市场价格和/或经营成果的负面影响，重大交易成本，未知负债，与收购或Cerevel业务相关的诉讼和/或监管行动风险，知识产权挑战，其他产品的竞争，研发固有的困难流程、不利诉讼或政府行为，以及适用于我们行业的法律法规的变化。

Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, 'Risk Factors,' of AbbVie's 2023 Annual .

有关可能影响艾伯维运营的经济、竞争、政府、技术和其他因素的更多信息，请参见艾伯维2023年年报第1A项“风险因素”。

SOURCE AbbVie

来源AbbVie